Das right.

Dasatinib (BCR-ABL inhibitor) expanded its FDA approval in the pediatric realm for newly diagnosed Philadelphia chromosome (Ph+, aka chromosome 9-22 translocation, aka BCR-ABL gene fusion) ALL—as opposed to Ph+ CML where dasatinib has been approved for over a decade in the adult setting. This all comes as with reporting of promising results of a single arm phase 2 trial adding dasatinib to standard chemo for kids with high-risk disease. | ASCO Post 2018